Search in the Abstract Database

Search Abstracts 2015

* = Presenting author

P084 Attributes of anti-TNF treatment that impact on preferences of patients with Crohn's disease candidates for biological treatment (IMPLICA Study)

N. Borruel*1, S. Riestra2, J. Castro3, M. Costi4, L. Rodriguez-San Pedro5, C. Taxonera6, F. Casellas7

1Hospital Vall d´Hebrón, , Digestive, Barcelona. , Spain, 2Hospital Central de Asturias,, Digestive, Oviedo, Spain, 3Hospital Arquitecto Marcide, , Digestive, Ferrol, Spain, 4Abbvie, Health Economics and Market Access, Madrid, Spain, 5Abbvie, Medical and Quality Assurance, Madrid, Spain, 6Hospital Clínico San Carlos, ., Digestive, Madrid. , Spain, 7Hospital Vall d´Hebrón, , Digestive , Barcelona, Spain


To identify attributes related to the biological treatment (BT) of moderate-severe Crohn's disease (CD) most highly valued by patients.


Observational, cross-sectional, multicentre study. Patients included were diagnosed with moderate-severe CD and were potential candidates for receiving any BT for CD. Patients answered IMPLICA-questionnaire to evaluate the preferences regarding treatment attributes. The questionnaire had 7 scenarios (A to F) with a combination of 3 attributes related to different characteristics of BT The scenarios were scored from 0 (I would never choose it) to 4 (I would always choose it). Conjoint analysis was used to measure the treatment preferences of patients. IMPLICA-questionnaire was provided prior to the visit. Investigator was aware of patient's preferred treatment but whose prescription was based on routine clinical practice.

scenarioRoute of AdministrationPerson Administering TreatmentPlace of Administration
AIntravenousHealthcare staffHospital
BIntravenousHealthcare staffOutpatients
CSubcutaneousHealthcare staffHospital
DSubcutaneousHealthcare staffOutpatients
ESubcutaneousHealthcare staffAt home
FSubcutaneousSelf-administrationAt home
GSubcutaneousFamily member or carerAt home


201 patients recruited by 19 Spanish gastroenterologists were included. 55.7% were male and mean(SD) age was 38.9(12.3) years. The mean(SD) disease duration was 8.6(8.1) years. Scenarios E and F were the most preferred (57.3% and 53.7% respectively). The place where the treatment is administered is the most influencing factor on patient's preference (importance of 50.7%). Patients who prefer treatment administered at home have a higher perceived health status versus patients who prefer treatment administered in hospital (p<0.01). Regarding route of administration, more patients preferred subcutaneous than intravenous treatment (70.1% vs 29.9%). Up to 68.7% of patients that preferred subcutaneous treatment chose treatment administered at home and 31.3% preferred treatment administered in hospital (by healthcare personnel). Patients aged 37 or older, students and housekeepers give the highest importance to whom administers the treatment, while patients aged <36 years and active workers give the highest importance to the place where the treatment is administered. Demographic and clinical profile was similar between patients that prefer hospital administration versus "at home" administration.


This study demonstrates that place and route of treatment administration have the greatest impact on patient preference for BT and that administration at home by subcutaneous via was the most preferred option of potential candidates for receiving BT. Age and working status have significant relevance in the patient's choice of BT. Knowing reasons for patient's election could help to optimize BT.